PSY17 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN MEXICO